Drug Farm Completes First Closing of $55 Million Series D Financing to Advance Clinical and Preclinical Development Pipeline
Click to view quick news summary (Spoiler)
Biotech innovator Drug Farm has secured $55 million in Series D financing to aggressively accelerate global clinical trials for its AI-developed candidates DF-003 and DF-006, targeting ROSAH syndrome, heart diseases, and Hepatitis B.
Drug Farm today officially announced the highly successful first closing of its $55 million Series D financing. The financing round was robustly co-led by the Shanghai Pudong Leading Area Investment Center and the Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise. This round also featured heavy participation from new investors including Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, and Keyuan Pharma. Furthermore, existing long-term investors, including BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, and Biometas, proudly participated in the round.
The vast proceeds from this financing will actively support the continued advancement of Drug Farm's clinical and preclinical stage pipeline, greatly accelerate global clinical development programs, strengthen critical regulatory activities across key global markets, and further expand the company's research and development capabilities.
"The successful completion of this financing represents an incredibly important milestone in Drug Farm's core mission to develop first-in-class drugs for the world," said Dr. Tian Xu, Founder and Chairman of Drug Farm. "We are deeply pleased to welcome our new investors while receiving continued, steadfast support from our long-term shareholders, reflecting strong market confidence in the company's scientific innovation, robust development strategy, and long-term vision. We truly believe this financing uniquely positions Drug Farm to create significant, long-lasting value for patients, partners, and shareholders in the years ahead.”
Dr. Henri Lichenstein, Chief Executive Officer of Drug Farm, enthusiastically added, "We are absolutely delighted to complete this financing and remain deeply grateful for the continued confidence and support from our investors. We are incredibly proud that DF-003 is amongst the very first drugs developed with AI drug discovery and entering a Phase 3 trial. The investment provides vital additional resources to seamlessly advance DF-003 through the completion of a pivotal trial in patients with ROSAH syndrome and to achieve clinical proof of concept in atherosclerotic cardiovascular disease. The funds will also be rapidly utilized to continue the clinical development of DF-006 in patients with hepatitis B."
Dr. Tony Xu, Chief Operating Officer of Drug Farm, proudly commented, "Powered completely by IDInVivo+ and MedChem5, our proprietary technology platforms seamlessly combining genetics and artificial intelligence continue to flawlessly discover and validate novel drug targets and rapidly advance multiple first-in-class candidates straight into the clinic. This financing will immensely help us bring additional breakthrough therapies directly to patients with unmet needs in metabolic and autoimmune diseases."
Drug Farm is a leading private biotechnology company actively developing highly innovative treatments for ROSAH syndrome, severe heart and kidney diseases, hepatitis B, and complex metabolic diseases. Its proprietary IDInVivo+ platform perfectly integrates genetics and artificial intelligence to identify and definitively validate novel drug targets directly in living systems. DF-003 is a proprietary, first-in-class drug that specifically inhibits the activity of ALPK1 and its disease-causing variants. It has demonstrated powerful evidence of clinical improvement across multiple symptoms of ROSAH syndrome in an ongoing Phase 1b study (NCT06395285). DF-003 has successfully received Fast Track, Orphan Drug, Rare Pediatric Disease, and Rare Disease Evidence Principles designations from the FDA, and its discovery was proudly published in Nature Communications.
DF-006 is a proprietary, first-in-class orally administered ALPK1 agonist immunomodulator that potently stimulates local, innate immunity directly within the liver. It has successfully completed single and multiple ascending dose (MAD) evaluation in healthy volunteers, and MAD evaluation in virologically suppressed HBeAg negative chronic hepatitis B (CHB) patients where highly encouraging anti-HBV activity was clinically observed. Its discovery was officially published in Hepatology, and Drug Farm alongside Xiamen Amoytop Biotech Co., Ltd. have entered into a massive clinical collaboration for DF-006 to effectively treat hepatitis B and hepatocellular cancer.
